Accretion Nutraveda’s record shows a clean audit opinion and no statutory defaults, but the cash engine is broken: revenue doubled in FY26 while operating cash flow sank to negative ₹9.42 crore, and the company now asks shareholders to approve a steep pay rise for six promoter-group directors.
Key findings
- Revenue doubled but turned into a cash drain
Major- Revenue rose from ₹16.00 crore in FY25 to ₹33.60 crore in FY26, yet operating cash flow swung from ₹-2.22 crore to ₹-9.42 crore and receivable days stretched from 75 to 88. Cumulative cash flow over FY23-FY26 was ₹-11 crore against cumulative profit of ₹9 crore, a cash conversion ratio of -1.24x. Management flags “Revenue concentration risk - significant share of income from a limited number of clients” as a weakness. - Six promoter-group directors seek identical monthly salaries of up to ₹5 lakh each
Major- The AGM notice proposes special resolutions for six promoter-group directors, Mr. Mayur Popatlal Sojitra, Mr. Paraskumar Vinubhai Parmar, Mr. Ankurkumar Shantilal Patel, Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashokkumar Patel, and Mr. Hardik Mukundbhai Prajapati, each at a monthly salary of up to Rs. 5,00,000 plus perquisites, with a clause that the company shall pay this as minimum remuneration in case of inadequate profits, for a three-year term. Their last-drawn annual remuneration in FY26 ranged from Rs. 6,30,200 to Rs. 13,10,600, while the proposed salary implies an annualised figure of up to Rs. 60,00,000 per director before perquisites. - The company’s gratuity plan contradicts its own statement on employee benefits
Minor- The company states it “does not have any Defined Contribution Plan or Defined Benefit Plan as contemplated under AS-15 on ‘Employee Benefits’”. However, the same annual report discloses a gratuity plan operated through a trust, presents actuarial tables, and recognises a gratuity expense of ₹2.00 lacs under “Defined Benefit Plan”.
What to watch
- IPO proceeds deployment. Unutilised IPO proceeds stood at 6.55 crore as at 31 March 2026, per the FY2025-26 Annual Report.
- Independent director appointments. Two independent directors, Mr. Chand Rameshbhai Kanabar and Ms. Grishma A Shewale, were appointed on 08 May 2026, each holding directorships in Accretion Pharmaceuticals Limited and Curis Lifesciences Limited, entities that share the “Accretion” name with the company or have overlapping board memberships.
Bottom line: This is a company with a clean statutory record and an auditor who signed off without reservation. The record is undermined by a cash conversion failure that deepened as revenue doubled, a remuneration proposal that asks shareholders to lock in large fixed pay for promoter directors regardless of profit, and a gratuity plan that contradicts the company’s own statement on employee benefits. Watch how the IPO proceeds are deployed and whether the new independent directors prove independent in practice.